$2.51 Billion is the total value of Cormorant Asset Management, LP's 67 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AXSM | New | AXSOME THERAPEUTICS INC | $62,016,000 | – | 600,000 | +100.0% | 2.48% | – |
| RETA | New | REATA PHARMACEUTICALS INCcall | $51,108,000 | – | 250,000 | +100.0% | 2.04% | – |
| VIE | New | VIELA BIO INC | $40,657,000 | – | 1,497,500 | +100.0% | 1.62% | – |
| ZYME | New | ZYMEWORKS INC | $31,822,000 | – | 700,000 | +100.0% | 1.27% | – |
| MYOV | New | MYOVANT SCIENCES LTD | $31,040,000 | – | 2,000,000 | +100.0% | 1.24% | – |
| CABA | New | CABALETTA BIO INC | $29,604,000 | – | 2,119,132 | +100.0% | 1.18% | – |
| IMVTU | New | IMMUNOVANT INCunit 12/18/2024 | $26,548,000 | – | 1,080,000 | +100.0% | 1.06% | – |
| OMER | New | OMEROS CORP | $21,487,000 | – | 1,525,000 | +100.0% | 0.86% | – |
| MRUS | New | MERUS N V | $14,080,000 | – | 1,000,000 | +100.0% | 0.56% | – |
| SRNE | New | SORRENTO THERAPEUTICS INC | $13,520,000 | – | 4,000,000 | +100.0% | 0.54% | – |
| CCXI | New | CHEMOCENTRYX INCcall | $9,888,000 | – | 250,000 | +100.0% | 0.40% | – |
| TBPH | New | THERAVANCE BIOPHARMA INC | $1,295,000 | – | 50,000 | +100.0% | 0.05% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.